Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Genetic Decryption of Leber Congenital Amaurosis (LCA) in a Large Cohort of Independent Families. (GENPHENACL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02970266
Recruitment Status : Completed
First Posted : November 21, 2016
Last Update Posted : November 21, 2016
Sponsor:
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris

Brief Summary:

The main objectives of this study are:

  1. Improve genetic counseling by establishment of prevalences of each of genetic subtypes within a expanded population of patients with LCA taking into account ethnicity of families.
  2. Confirm, refine or modify the genotype-phenotype correlations.
  3. Edit important recommendations for:

    • The clinical and paraclinical exploration of a new patient based on genotype, especially for extraocular explorations, to book at certain genetic subtypes
    • Prenatal care of a couple.
    • Directing families to a therapeutic protocol in progress or in development.
  4. Individualize a panel of families without a mutation in the known genes and identify new genes responsible.

Condition or disease
Leber Congenital Amaurosis

Detailed Description:

This study characterize the clinical history of the disease (age and start mode of visual disturbances, rate and mode of progress of disease), careful assessment of retina function and finally, in search of the mutations responsible for this condition.

A full ophthalmic check-up, one at the inclusion and 24 months :

  1. - A genetic consultation taking account of family history and establishment of family tree with precision of geographical origin of birth of ascendants.
  2. - A thorough ophthalmologic examination by a referring medical ophthalmologist, including:

    2.1 - An interrogation on the development of the visual awakening since the birth and its possible disturbances.

    2.2 - The search for abnormal movements of the eyeballs, and difficulties with regard to different lighting.

    2.3 - Visual field evaluation Survey.

    2.4 - The study of color vision.

    2.5 - The search for a refractive disorder with the automatic refractometer.

    2.6 - Measurement of Visual acuity for near and distance.

    2.7 - Examination of the eyeball as a whole, examination of the anterior chamber of the eye by the slit lamp.

    2.8 - Taking pictures of the fundus of the eye after pupillary dilation.

    2.9 - An autofluorescence search using a Scanning Laser Ophthalmoscopy (SLO).

    2.10 - Optical Coherence Tomography (OCT) which used to assess the thickness of each of retinal layers.

    2.11 - Electrophysiological examination, Electroretinogram (ERG) that allows to record the functional value of the retina.

    These two latter examinations last on average 10 minutes after dilation of the pupil.

  3. - A blood sample of 10 milliliters to carry out genetic studies to identify the gene responsible for this condition and genetic counseling refined by taking account the results of this study.

Intermediate visit M12: only for patients younger than 6 years of age on inclusion.

Layout table for study information
Study Type : Observational
Actual Enrollment : 659 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Genetic Decryption of Leber Congenital Amaurosis (LCA) in a Large Cohort of Independent Families: Establishment of Genotype-phenotype Correlations and Updating the Clinical Definition of This Retinal Dystrophy
Study Start Date : September 2010
Actual Primary Completion Date : September 2015
Actual Study Completion Date : November 2016

Resource links provided by the National Library of Medicine





Primary Outcome Measures :
  1. Improve genetic counseling by establishment of prevalences of each of genetic subtypes within a expanded population of patients with LCA. [ Time Frame: 24 MONTHS ]

Secondary Outcome Measures :
  1. Measurement of visual acuity using the logarithmic scale for children under 5 [ Time Frame: 24 MONTHS ]
  2. Measurement of visual acuity using Early Treatment Diabetic Retinopathy Study scale (ETDRS) for far vision [ Time Frame: 24 MONTHS ]
  3. The "Parinaud Scale" for near vision (After the age of 6) [ Time Frame: 24 MONTHS ]
  4. Visual field evaluation Survey [ Time Frame: 24 MONTHS ]
  5. Measurement of refraction by portable automatic refractometer. [ Time Frame: 24 MONTHS ]
  6. Screening for color vision abnormalities using "children's boards" of "Ishihara Test" from the age of 3-4. [ Time Frame: 24 MONTHS ]
  7. Screening for color vision abnormalities using "regular boards" as soon as learning to read figures from the age of five. [ Time Frame: 24 MONTHS ]
  8. Test the color vision deficiency using the " Farnsworth test" in adults and children after the age of 6. [ Time Frame: 24 MONTHS ]
  9. The visual field test using the Goldman dome in adults and children aged 6 to 7. [ Time Frame: 24 MONTHS ]
  10. Electrophysiological examination using Electroretinogram. [ Time Frame: 24 MONTHS ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Patients with Leber Congenital Amaurosis (LCA) taking into account Ethnicity of families.
Criteria

Inclusion Criteria:

Patients:

  • Patients of all ages
  • Patients with symptoms the day of the first consultation allowing to ask the diagnosis of leber congenital amaurosis.
  • Are affiliated to a social health care.
  • Written informed consent must be given by patients or holders parental authority for minors.

patients and siblings:

  • Signed consent for molecular study by the participant or by holders parental authority for minors.
  • Are affiliated to a social health care.

Exclusion Criteria:

  • Patients whose exploration has laid differential diagnoses.
  • Patients refusing the visits provided for in Protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02970266


Locations
Layout table for location information
France
Necker-Enfants Malades Hospital
Paris, France, 75015
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Investigators
Layout table for investigator information
Principal Investigator: Josseline KAPLAN, MD Necker-Enfants Malades Hospital, 75015 Paris. France
Layout table for additonal information
Responsible Party: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT02970266    
Other Study ID Numbers: P081257
First Posted: November 21, 2016    Key Record Dates
Last Update Posted: November 21, 2016
Last Verified: November 2016
Keywords provided by Assistance Publique - Hôpitaux de Paris:
Leber Congenital Amaurosis
Genetic Decryption
The genotype-phenotype correlations
Ethnicity families
Additional relevant MeSH terms:
Layout table for MeSH terms
Blindness
Leber Congenital Amaurosis
Vision Disorders
Sensation Disorders
Neurologic Manifestations
Nervous System Diseases
Eye Diseases
Eye Diseases, Hereditary
Retinal Diseases